Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial

Roche mixes Actemra with Gilead's remdesivir in COVID-19 trial

Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc’s anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday.


Actemra and remdesivir are being used separately in some settings and clinical trials, Reuters reports.  

Roche is hoping that by combining the two in a global study of 450 hospitalised patients worldwide, it will be able to offer doctors a one-two punch against the disease that has so far stricken 5.8 million people and killed nearly 360,000. The cocktail will be compared against remdesivir and a placebo.


Based on our current understanding, we believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease,” Roche Chief Medical Officer Levi Garraway said in a statement.


Remdesivir, a failed Ebola drug repurposed against the new coronavirus amid the COVID-19 pandemic, has captured lots of attention after a 397-patient study showed it helped reduce time of recovery in some patients and suggested it helped keep people alive.


The drug is currently undergoing clinical trials around the world, including in the UK.

Early data suggests it can cut recovery time by about four days, but there is no evidence yet that it will save more lives.


Roche is also studying Actemra, originally developed for arthritis but also used to control immune reactions in some cancer patients, as a monotherapy in a separate trial of 450 patients due to complete enrolment soon and produce results later this year.